MCID: HPT007
MIFTS: 54

Hepatitis E malady

Categories: Rare diseases, Skin diseases, Infectious diseases, Genetic diseases, Liver diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Hepatitis E

Aliases & Descriptions for Hepatitis E:

Name: Hepatitis E 12 50 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4411
MeSH 42 D016751
SNOMED-CT 64 7111000119109
UMLS 69 C0085293

Summaries for Hepatitis E

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis E virus, which is transmitted_by ingestion of contaminated food. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom dark urine, has symptom joint pain, and has symptom jaundice.

MalaCards based summary : Hepatitis E is related to hepatitis and b-cell lymphomas, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis E is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-KappaB Family Pathway. The drugs Aluminum hydroxide and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are endocrine/exocrine gland and reproductive system

Wikipedia : 71 Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis... more...

Related Diseases for Hepatitis E

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis E via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
id Related Disease Score Top Affiliating Genes
1 hepatitis 31.4 HLA-DRB1 IFNG TNF
2 b-cell lymphomas 29.1 CD40LG F2 GPT HLA-DRB1
3 membranoproliferative glomerulonephritis 29.0 ALB CD40LG F2 RPS17 TNF
4 nondystrophic myotonia 10.3 ALB F2
5 congenital dyserythropoietic anemia 10.3 ALB TNF
6 familial progressive hyperpigmentation 10.3 F2 GPT
7 bile duct adenocarcinoma 10.3 ALB CD40LG
8 colloid adenoma 10.3 ALB CD40LG
9 stocco dos santos syndrome 10.2 IFNG TNF
10 estrogen excess 10.2 ALB CD40LG
11 rosacea 10.2 ALB GPT IFNG
12 female infertility of uterine origin 10.2 ALB F2 GPT
13 bile duct cystadenocarcinoma 10.2 ALB F2 GPT
14 autosomal dominant deafness-onychodystrophy syndrome 10.2 IFNG TNF
15 kohler's disease 10.2 ALB F2 GPT
16 isolated growth hormone deficiency 10.2 ALB GPT IFNG
17 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.2 ALB F2 GPT
18 acute monocytic leukemia 10.2 ALB F2 GPT
19 ovarian papillary cystadenoma 10.2 ALB F2 IFNG
20 pyelitis 10.2 ALB F2 GPT
21 maxillary sinusitis 10.2 CD40LG F2 GPT
22 pulpitis 10.2 F2 IFNG TNF
23 fallopian tube leiomyosarcoma 10.2 ALB F2 GPT
24 gastrointestinal adenoma 10.2 ALB F2 GPT
25 paralytic poliomyelitis 10.2 IFNG TLR3
26 lubinsky syndrome 10.2 CD40LG F2
27 bladder sarcoma 10.2 ALB GPT TNF
28 hypertropia 10.2 ALB IFNG TNF
29 infiltrating ureter transitional cell carcinoma 10.2 ALB F2 TNF
30 freiberg's disease 10.2 ALB CD40LG F2
31 parovarian cyst 10.2 F2 TNF
32 chronic inflammatory demyelinating polyneuritis 10.2 ALB CD40LG F2
33 rift valley fever 10.2 ALB IFNG TNF
34 conduct disorder 10.2 CD40LG IFNG TNF
35 mansonelliasis 10.2 ALB IFNG TNF
36 tularemia 10.2 CD40LG IFNG TNF
37 israeli tick typhus 10.2 CD40LG IFNG
38 oral cavity cancer 10.2 CD40LG IFNG TNF
39 rickettsialpox 10.2 CD40LG IFNG TNF
40 liver inflammatory pseudotumor 10.2 ALB IFNG TNF
41 myiasis 10.2 CD40LG IFNG TNF
42 dermatomycosis 10.2 ALB CD40LG TNF
43 atrophy of prostate 10.2 CD40LG F2 TNF
44 motor peripheral neuropathy 10.2 CD40LG IFNG TNF
45 asbestosis 10.2 ALB F2 TNF
46 hyperimmunoglobulin syndrome 10.2 CD40LG IFNG TNF
47 pigmentation disease 10.2 ALB IFNG TNF
48 hallucinogen dependence 10.2 CD40LG IFNG TNF
49 obstructive jaundice 10.2 ALB F2 TNF
50 keratomalacia 10.2 CD40LG IFNG TNF

Graphical network of the top 20 diseases related to Hepatitis E:



Diseases related to Hepatitis E

Symptoms & Phenotypes for Hepatitis E

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • dark urine
  • joint pain
  • jaundice

MGI Mouse Phenotypes related to Hepatitis E:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.56 ALB ASZ1 BTRC CD40LG FGB IFNG
2 reproductive system MP:0005389 9.23 FGB IFNG TLR3 TNF ASZ1 BTRC

Drugs & Therapeutics for Hepatitis E

Drugs for Hepatitis E (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 370)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 1 21645-51-2
2
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2 142340-99-6 60871
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
7
Amantadine Approved Phase 4,Phase 3 768-94-5 2130
8
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
9
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
10
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
13
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
14
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
15
Nevirapine Approved Phase 4,Phase 2,Phase 3 129618-40-2 4463
16
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3 3056-17-5 18283
17
Pravastatin Approved Phase 4,Phase 1 81093-37-0 54687
18
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
19
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Ibuprofen Approved Phase 4 15687-27-1 3672
23
Ledipasvir Approved Phase 4,Phase 3,Phase 2 1256388-51-8 67505836
24
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
25
Sofosbuvir Approved Phase 4,Phase 3,Phase 2 1190307-88-0 45375808
26
Ethanol Approved Phase 4,Phase 3,Phase 1 64-17-5 702
27
Cobicistat Approved Phase 4,Phase 3 1004316-88-4
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
30
Mycophenolic acid Approved Phase 4 24280-93-1 446541
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Early Phase 1 59-02-9 14985
32 Aluminum sulfate Phase 4,Phase 3,Phase 1
33 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
34 Adefovir Phase 4,Phase 3,Phase 2
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Chlorhexidine gluconate Phase 4
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Anticholesteremic Agents Phase 4,Phase 2,Phase 1
44 Antihypertensive Agents Phase 4,Phase 1
45 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antioxidants Phase 4,Phase 3,Phase 2,Early Phase 1
47 Antitubercular Agents Phase 4,Phase 2,Phase 3
48 Essential 303 forte Phase 4
49 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 499)
id Name Status NCT ID Phase
1 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
2 3E Extension Study Unknown status NCT01834508 Phase 4
3 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
4 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
5 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
6 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
7 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4
8 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
9 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4
10 A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli) Completed NCT02417597 Phase 4
11 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Completed NCT00393484 Phase 4
12 A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) Completed NCT02570191 Phase 4
13 Factors Associated to Success of Hepatitis C Therapy Completed NCT00514111 Phase 4
14 A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B Completed NCT02598063 Phase 4
15 A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) Completed NCT02604823 Phase 4
16 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4
17 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B Completed NCT00922207 Phase 4
18 To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB) Completed NCT00537537 Phase 4
19 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. Completed NCT01519921 Phase 4
20 Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) Completed NCT01937728 Phase 4
21 A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Completed NCT02641379 Phase 4
22 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program Completed NCT02791269 Phase 4
23 Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg) Completed NCT00240539 Phase 4
24 Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy Completed NCT00351871 Phase 4
25 Long-term Study With Clevudine Completed NCT00558818 Phase 4
26 Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B Completed NCT00877149 Phase 4
27 Hepatitis B Vaccination in HIV-infected Adults Completed NCT02713620 Phase 4
28 Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B Completed NCT00324961 Phase 4
29 An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB) Completed NCT01205165 Phase 4
30 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB Completed NCT01320943 Phase 4
31 Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC Completed NCT00207363 Phase 4
32 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C Completed NCT01925183 Phase 4
33 Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV Completed NCT01637844 Phase 4
34 A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection Completed NCT02339337 Phase 4
35 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
36 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
37 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
38 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4
39 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
40 Suboptimal Responders to Adefovir Switching to Entecavir Completed NCT00718887 Phase 4
41 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4
42 Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection Completed NCT00127959 Phase 4
43 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4
44 Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Recruiting NCT02558114 Phase 4
45 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Recruiting NCT01925820 Phase 4
46 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Recruiting NCT01906580 Phase 4
47 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Recruiting NCT02523547 Phase 4
48 Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy Recruiting NCT02594293 Phase 4
49 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
50 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Recruiting NCT02973646 Phase 4

Search NIH Clinical Center for Hepatitis E

Cochrane evidence based reviews: hepatitis e

Genetic Tests for Hepatitis E

Anatomical Context for Hepatitis E

MalaCards organs/tissues related to Hepatitis E:

39
Liver, Kidney, T Cells, Testes, Skin, Heart, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis E:

18
Liver

Publications for Hepatitis E

Articles related to Hepatitis E:

(show top 50) (show all 716)
id Title Authors Year
1
Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. ( 28078736 )
2017
2
High frequency of hepatitis E virus infection in swine from South Brazil and close similarity to human HEV isolates. ( 28089613 )
2017
3
Hepatitis E virus seroprevalence among the general population in a livestock-dense area in the Netherlands: a cross-sectional population-based serological survey. ( 28056844 )
2017
4
Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection? ( 28077520 )
2017
5
Phylogenetic analysis of Hepatitis E virus strains isolated from slaughter-age pigs in Colombia. ( 28063923 )
2017
6
A Acute hepatitis E mimicking a flare of disease in a patient with chronic autoimmune hepatitis. ( 28051806 )
2017
7
Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation. ( 28067868 )
2017
8
A High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India. ( 28051793 )
2017
9
Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption. ( 28067990 )
2017
10
Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. ( 28439773 )
2017
11
Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. ( 28077314 )
2017
12
Hepatitis E virus seroprevalence among farmers, veterinarians and control subjects in Jilin province, Shandong province and Inner Mongolia Autonomous Region, China. ( 27664799 )
2016
13
Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients. ( 27991886 )
2016
14
Hepatitis E virus in acute liver failure: An unusual suspect? ( 27496198 )
2016
15
Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. ( 27110256 )
2016
16
Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. ( 27174035 )
2016
17
Hepatitis E Virus in Industrialized Countries: The Silent Threat. ( 28070522 )
2016
18
Clinical features of acute hepatitis E super-infections on chronic hepatitis B. ( 28058019 )
2016
19
Hepatitis E Virus: Time to Change the Textbooks. ( 27170383 )
2016
20
Advances in hepatitis E - I: virology, pathogenesis and diagnosis. ( 27159083 )
2016
21
Thermal stability of hepatitis E virus estimated by a cell culture method. ( 27208095 )
2016
22
An updated approach to viral hepatitis E. ( 28078902 )
2016
23
No evidence of rat hepatitis E virus excretion into urine of rats. ( 27580584 )
2016
24
Hepatitis E virus ORF1 encoded macro domain protein interacts with light chain subunit of human ferritin and inhibits its secretion. ( 27170377 )
2016
25
Hepatitis E in decompensated alcoholic cirrhosis. ( 27617933 )
2016
26
Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin. ( 27470489 )
2016
27
Treatment of hepatitis E virus. ( 27607911 )
2016
28
Detection of hepatitis E virus (HEV) in goats. ( 27647265 )
2016
29
Surveillance at Private Laboratories Identifies Small Outbreaks of Hepatitis E in Urban Bangladesh. ( 27994104 )
2016
30
Hepatitis E Virus in Farmed Rabbits, Wild Rabbits and Petting Farm Rabbits in the Netherlands. ( 27147250 )
2016
31
Detection of Hepatitis E Virus Genotype 1 Among Blood Donors From Southwest of Iran. ( 27630719 )
2016
32
Production of monoclonal antibodies against the ORF3 protein of rat hepatitis E virus (HEV) and demonstration of the incorporation of the ORF3 protein into enveloped rat HEV particles. ( 27638774 )
2016
33
Identification of Distribution Characteristics and Epidemic Trends of Hepatitis E in Zhejiang Province, China from 2007 to 2012. ( 27146250 )
2016
34
A Korean patient with Guillain-BarrAc syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy. ( 27572076 )
2016
35
Genotype 1 hepatitis E virus infection with acute acalculous cholecystitis as an extrahepatic symptom: a case report. ( 27433137 )
2016
36
Specific memory B cell response and participation of CD4(+) central and effector memory T cells in mice immunized with liposome encapsulated recombinant NE protein based Hepatitis E vaccine candidate. ( 27997340 )
2016
37
Molecular Biology and Infection of Hepatitis E Virus. ( 27656178 )
2016
38
Seroprevalence of Hepatitis E Virus Antibodies in Portuguese Children. ( 28033239 )
2016
39
Hepatitis E in blood donors: investigation of the natural course of asymptomatic infection, Germany, 2011. ( 27608433 )
2016
40
Detection of Hepatitis E Virus in Sewage After an Outbreak on a French Island. ( 27165600 )
2016
41
The role of hepatitis E virus infection in Adult Americans with acute liver failure. ( 27215797 )
2016
42
Hepatitis E virus genotype 3 in mussels (Mytilus galloprovinciallis), Spain. ( 27217353 )
2016
43
Identification and characterization of avian hepatitis E virus genotype 2 from chickens with hepatitis-splenomegaly syndrome in Korea. ( 27164843 )
2016
44
Markers for Ongoing or Previous Hepatitis E Virus Infection Are as Common in Wild Ungulates as in Humans in Sweden. ( 27657108 )
2016
45
Knowledge Is Safety: The Time Is Ripe for Hepatitis E Virus Blood Donor Screening. ( 27994530 )
2016
46
Transcriptome Analysis of HepG2 Cells Expressing ORF3 from Swine Hepatitis E Virus to Determine the Effects of ORF3 on Host Cells. ( 27648443 )
2016
47
Prevalence of hepatitis E virus infection among blood donors in mainland China: a meta-analysis. ( 28035774 )
2016
48
Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus. ( 27194006 )
2016
49
Hepatitis E: latest developments in knowledge. ( 27203841 )
2016
50
A Study of Hepatitis E in Pregnancy: Maternal and Fetal Outcome. ( 27651572 )
2016

Variations for Hepatitis E

Expression for Hepatitis E

Search GEO for disease gene expression data for Hepatitis E.

Pathways for Hepatitis E

Pathways related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 BTRC CD40LG FGB HLA-DRB1 IFNG TNF
2
Show member pathways
12.43 BTRC CD40LG TLR3 TNF
3
Show member pathways
12.35 CD40LG HLA-DRB1 IFNG TNF
4 12.23 CD40LG IFNG TLR3 TNF
5
Show member pathways
11.89 ALB F2 IFNG TNF
6
Show member pathways
11.73 CD40LG HLA-DRB1 IFNG TNF
7
Show member pathways
11.66 IFNG TLR3 TNF
8 11.53 HLA-DRB1 IFNG TNF
9
Show member pathways
11.43 CD40LG IFNG TNF
10
Show member pathways
11.3 CD40LG IFNG TNF
11 10.89 BTRC TNF
12 10.82 CD40LG IFNG TNF
13 10.28 HLA-DRB1 IFNG TNF

GO Terms for Hepatitis E

Cellular components related to Hepatitis E according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 CD40LG FGB HLA-DRB1 TLR3 TNF
2 extracellular space GO:0005615 9.5 ALB CD40LG F2 FGB GPT IFNG
3 external side of plasma membrane GO:0009897 9.1 CD40LG F2 FGB HLA-DRB1 IFNG TNF

Biological processes related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.77 BTRC HLA-DRB1 IFNG
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.74 CD40LG TLR3 TNF
3 platelet activation GO:0030168 9.7 CD40LG F2 FGB
4 response to virus GO:0009615 9.67 IFNG TLR3 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.62 F2 IFNG TLR3 TNF
6 positive regulation of NF-kappaB import into nucleus GO:0042346 9.59 TLR3 TNF
7 fibrinolysis GO:0042730 9.58 F2 FGB
8 positive regulation of osteoclast differentiation GO:0045672 9.58 IFNG TNF
9 positive regulation of chemokine production GO:0032722 9.56 TLR3 TNF
10 negative regulation of growth of symbiont in host GO:0044130 9.55 IFNG TNF
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.54 IFNG TNF
12 extrinsic apoptotic signaling pathway GO:0097191 9.54 IFNG TLR3 TNF
13 positive regulation of exosomal secretion GO:1903543 9.51 IFNG VPS4A
14 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.48 BTRC TNF
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.46 FGB TNF
16 necroptotic signaling pathway GO:0097527 9.43 TLR3 TNF
17 regulation of immunoglobulin secretion GO:0051023 9.4 CD40LG TNF
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
19 positive regulation of vitamin D biosynthetic process GO:0060557 9.16 IFNG TNF
20 positive regulation of interleukin-12 production GO:0032735 9.13 CD40LG IFNG TLR3
21 positive regulation of chemokine biosynthetic process GO:0045080 8.8 IFNG TLR3 TNF

Sources for Hepatitis E

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....